Canada Markets closed

Poxel S.A. (PXXLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.60000.0000 (0.00%)
At close: 10:40AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close2.6000
Open2.6000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.6000 - 2.6000
52 Week Range2.1000 - 5.8250
Volume1,000
Avg. Volume0
Market Cap65.223M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-1.3980
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Poxel Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment of Adrenoleukodystrophy

    LYON, France, January 25, 2023--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that European Commission has granted orphan drug designation (ODD) for PXL770 and PXL065 for the treatment of adrenoleukodystrophy (ALD). The decision follows a positive opinion from the Committ

  • Business Wire

    Poxel Announces Upcoming Participation at Investor Conferences

    LYON, France, January 04, 2023--POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its upcoming participation at conferences organized by Oddo BHF and Degroof Petercam to be held in January 2023.

  • Business Wire

    Poxel Announces its Financial Calendar for 2023

    LYON, France, January 03, 2023--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2023.